Perseus Proteomics Inc
TSE:4882
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Perseus Proteomics Inc
TSE:4882
|
3.5B JPY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.3B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
89.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -122 700% |
| 30th Percentile | 2.9% |
| Median | 5.4% |
| 70th Percentile | 8.5% |
| Max | 63 031.4% |
Other Profitability Ratios
Perseus Proteomics Inc
Glance View
Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Perseus Proteomics Inc is -646.8%, which is above its 3-year median of -908.2%.
Over the last 3 years, Perseus Proteomics Inc’s Net Margin has increased from -764.5% to -646.8%. During this period, it reached a low of -1 168.7% on Dec 31, 2023 and a high of -646.8% on Sep 30, 2025.
